论文部分内容阅读
水扬酸偶氮磺胺吡啶(SASP)广泛用于治疗溃疡性结肠炎。但约三分之一的患者出现副作用,现认为与其中的磺胺吡啶有关。奥尔沙拉嗪(Olsalazine,OS)是一种新近合成的无磺胺成分的药物,但9.8％的病人服药后发生腹泻。最近动物实验提示该药可能对小肠葡萄糖、水和电解质吸收有损害作用。本文研究的目的是观察OS和SASP对正常人体小肠水、葡萄糖和电解质吸收的影响。方法:28例正常人(平均年龄26岁)作了小肠灌注试验,其中16例作空肠灌注,12例作回肠灌注。受
Sulphasalazine (SASP) is widely used in the treatment of ulcerative colitis. However, about one-third of patients have side effects and are considered to be associated with sulfapyridine. Olsalazine (OS) is a newly synthesized drug with no sulfonamide but diarrhea occurs in 9.8% of patients. Recent animal experiments suggest that the drug may have impaired intestinal glucose, water and electrolyte absorption. The purpose of this study was to investigate the effects of OS and SASP on the absorption of small intestine water, glucose and electrolytes in normal humans. METHODS: Twenty-eight normal subjects (mean age 26 years) underwent small intestinal perfusion test, of which 16 were jejunal perfusion and 12 were ileal perfusion. By